CHIP-D: Circadian Health In Psychosis And Depression
Overview
The CHiP-D research study, funded by the Wellcome Trust, is investigating how sleep patterns and circadian rhythms influence cognitive and emotional well-being. This study explores how variations in sleep and biological rhythms affect how we think, feel, and function in daily life. Further information can be found here.
What will it involve?
You will complete a 14-day monitoring period once in each season of the year (spring, summer, autumn, and winter). During this time, you will wear devices that track your sleep, activity, and light exposure and complete brief daily smartphone tasks. You will also provide saliva samples on three days. At the end of each monitoring period, you will have a low-field MRI scan.
Who are we looking to recruit?
We are looking to recruit people for three separate groups. You may be eligible to take part if:
1. Healthy group: You work full-time standard daytime hours (e.g., 9 am – 5 pm) and do not have a current sleep or mental health diagnosis.
2. NHS shift worker group: You are an NHS staff member working a rotational shift schedule and do not have a current sleep or mental health diagnosis.
3. Clinical group: You have received a formal diagnosis of major depressive disorder, schizophrenia or schizophreniform disorder.
You must be aged between 18 and 55 years and willing to travel to one of our research sites, located in Canterbury or at the Denmark Hill campus of King’s College London.
Rewards and expenses
You will receive a total of £210 in vouchers, awarded incrementally after each season.
Are you interested in taking part in this study?
Planned end date
01 Sep 2028 11:54Conditions
Depression,PsychosisPeople types
Adult 18+Inclusion Criteria
1. Males and females aged 18-55; upper age limit established to minimise potential cognitive impairments
2. Physically healthy (i.e., without significant neurological disease, mental disorder or systemic illness as detailed in the exclusion criteria)
3. Sufficient command of English, i.e., be able to read, write, and speak the language in which psychometric tests, informed consent form (ICF) and participant information sheet (PIS) are provided, with acceptable auditory acuity (corrected if necessary)
4. Capacity to provide written consent
5. Have a smartphone able to load and access website/messages and be willing to use it as the main interface for the study. An alternative device will be available for eligible participants with a mobile device that does not support access website/messages or participants lacking adequate resources
Additional inclusion criteria for standard workers:
6. No personal or family history of psychosis/depression
7. Currently in active employment (standard working hours)
8. No sleep or affective disorder
Additional criteria for shift workers:
9. No personal or family history of psychosis/depression
10. Currently in active employment (non-standard working hours)
11. No sleep or affective disorder
Additional criteria for clinical population:
10. DSM-5 diagnosis of schizophrenia or schizophreniform disorder or major depressive disorder respectively with onset in the last 10 years
11. Stable on current treatment for at least 3 months prior to enrolment phase.
12. No more than 2 anti-psychotic or antidepressant medications.
Exclusion Criteria
All participants must not:
1. If female, be pregnant
2. With exception of the clinical group, have a diagnosis of any clinically significant neurological disease or mental disorder according to judgment of the investigator (e.g. multiple sclerosis, epilepsy, dementia and autism).
3. Have a history of severe learning disability accordingly to the judgment of the investigator
4. Have a history of substance use disorder according to DSM-5 criteria, except nicotine or caffeine, within 6 months prior to the enrolment phase
5. Have had major surgery, (e.g., requiring local or general anaesthesia) within 12 weeks prior to the enrolment, or will not have fully recovered from surgery, or have surgery planned during the time they are expected to participate in the study
6. Have used cannabis in the 12 hours before cognitive testing
7. Are likely to present a danger to themselves or others
8. Have a current serious or instable clinical important systemic illness (e.g., hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrinologic, immunologic, hematologic, or ocular disorders, insulin-dependent diabetes, diagnosis of cancer in the previous 6 months) that in the judgement of the investigator may affect their ability to complete the assessments in the study
9. Are unlikely to comply with the protocol or are unsuitable for any reason
10. Have any MRI scanning contraindications (e.g. presence of pacemakers, metallic implants, claustrophobia)